Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
(benzylamino)(oxo)acetic acid
(heptylamino)(oxo)acetic acid
(hexylamino)(oxo)acetic acid
(nonylamino)(oxo)acetic acid
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
1,6-dibromo-2-hydroxynaphthalene 3-carboxylic acid
-
0.31 mM
1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indol-2-carboxylic acid
a N-hydroxyindole, NH1-1, and a competitive inhibitor with respect to both NADH and pyruvate
1-[7-[3,4-dihydroxy-2-imino-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-8-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalen-1-yl]ethanone
2,3-dihydroxy-4,6,7-trimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)-7-[4-(trifluoromethyl)benzyl]naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(2-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(3-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,3-dihydroxy-6-methyl-7-(4-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
2,6-naphthalene disulfonic acid
-
IC50: 21 mM
2,6-naphthalenedicarboxalic acid
-
IC50: 5.1 mM
2-mercaptoethanol
10% inhibition at 1 mM
3,5-dihydroxy 2-naphthoic acid
-
IC50: 1.7 mM
3,5-dihydroxynaphthalene-2-carboxylic acid
3,7-dihydroxy naphthalene-2-carboxylic acid
-
IC50: 2.4 mM
3,7-dihydroxynaphthalene-2-carboxylic acid
3-((3-carbamoyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxyquinolin-4-yl) amino) benzoic acid
a quinoline-3-sulfonamide, competitive inhibitor with respect to both NADH and pyruvate
3-(3-nitro-4-pyridyl)pyruvate
-
-
3-(3-nitropyridin-4-yl)-2-oxopropanoic acid
-
-
3-([3-carbamoyldimethoxypyrimidin-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino)benzoic acid
enzyme binding structure, overview
3-acetylpyridine adenine dinucleotide
-
the enzyme exhibits characteristic reduced substrate inhibition and enhanced kcat
3-Aminopyridine adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
3-hydroxy-1,2-oxazole-4-carboxylic acid
-
-
3-hydroxy-1-oxaspiro[4.5]dec-3-en-2-one
-
-
3-hydroxy-2-oxo-1-oxaspiro[4,5]-dec-3-ene
-
-
3-[7-(2,4-dimethoxypyrimidin-5-yl)-3-sulfamoylquinolin-4-yl]aminobenzoic acid
enzyme binding structure, overview
4,7-dibromo-3-hydroxynaphthalene-2-carboxylic acid
4-(ethylcarbamoyl)benzoic acid
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid
-
-
4-hydroxy-1,2-oxazole-3-carboxylic acid
-
-
6,6'-disulfanediyldipyridine-3-carboxylic acid
6,6'-Dithiodinicotinic acid
-
IC50: 6.6 mM
6-benzyl-3,4-dihydroxy-7-methyl-1-propylnaphthalene-2-carboxylic acid
FX11, a competitive inhibitor with respect to both NADH and pyruvate
7-(4-chlorobenzyl)-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
8'-acetyl-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8-carboxylic acid
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl acetate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl butanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl pentanoate
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl propanoate
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-(phenylamino)naphthalene-1-sulfonic acid
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
8-anilino-1-naphthalene sulfonic acid
-
IC50: 0.52 mM
8-[8-acetyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-3,4-dihydroxy-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-2-one
Alpha-NAD+
-
noncompetitive inhibitor versus beta-NAD+
ascorbate
-
at concentrations normally found in tissue. It is proposed that ascorbate facilitates the storage of glycogen in muscle at rest by inhibiting glycolysis. Aldolase and muscle G-actin protect and reverse inhibition
AZ-33
a malonic derivative, a competitive inhibitor with respect to both NADH and pyruvate
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')copper
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')zinc
cardiolipin
-
IC50: 0.00005 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
Chinese gall
ethanol extract of the Chinese gall, commonly named Wu Bei Zi, strongly inhibits the enzyme
-
citrate/phosphate buffer
-
at pH 5.4
Cu[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, heart, spleen, brain and skeletal muscle tissues, overview
D-fructose 1,6-bisphosphate
D-fructose-1,6-diphosphate
-
5 mM, 25% loss of activity
D-lactate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
dicholesteroyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by dicholesteroyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Exerts profound concentration dependent inhibitory effect on the activity of renal LDH. Inhibitory effect on hepatic LDH is markedly pronounced at 2, 4, 8 and 10 microM. Strongly inhibits cardiac LDH activity when NAD+ is omitted from the pre-incubating medium than when lactate is absent from the pre-incubating medium, significantly inhibits the enzyme activity at 1, 2, 4, and 8 microM
dihydroxyacetone phosphate
-
-
diphenyl diselenide
-
inhibition of different isoforms of lactate dehydrogenase by diphenyl diselenide possibly involves the modification of the thiol groups at the NAD+ binding site of the enzyme. Inhibitory effect on hepatic LDH is markedly different at 10 microM. Markedly inhibits cardiac LDH activity at 8 and 10 microM
DTT
19% inhibition at 1 mM
epigallocatechin
the most potent compound with anti-LDH-5 activity under both normoxia and hypoxia conditions
ethyl 3-(3-cyano-4-pyridyl)pyruvate
-
-
ethyl 3-(3-cyanopyridin-4-yl)-2-oxopropanoate
-
-
Fe3+
complete inhibition at 1 mM
fructose 1,6-bisphosphate
galloflavin
a blocker of LDH-5-ssDNA interactions, preventing RNA synthesis
glutamate
-
both directions
GNE-140
a piperidine derivative LDH-5 inhibitor
gossylic nitrile 1,1'-diacetate
Lactate
-
a high concentration of lactate has a weak inhibitory effect on the pyruvate reduction reaction activity but is meaningful for a significant lactate oxidation rate as the K m value of LDHA for L-lactate is very high
methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)-1H-indol-2-carboxylate
a N-hydroxyindole, NH1-2, and a competitive inhibitor with respect to both NADH and pyruvate
NaCl
-
2 M, 36% loss of activity
NADH
-
competitive with respect to NAD+
naphthalene-2,6-dicarboxylic acid
naphthalene-2,6-disulfonic acid
nicotinic acid adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
o-phthalaldehyde
-
modification not only results in inactivation of the enzyme, but also leads to the enzymes dissociation and partial unfolding
oxo(pentadecylamino)acetic acid
oxo(phenylamino)acetic acid
oxo[(2-phenylethyl)amino]acetic acid
oxo[(2-phenylpropyl)amino]acetic acid
oxo[(3-phenylpropyl)amino]acetic acid
oxo[(4-phenylbutan-2-yl)amino]acetic acid
oxo[(4-phenylbutyl)amino]acetic acid
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
phosphatidylserine
-
IC50: 0.0013 mM, interaction with acidic phospholipids is most efficient at pH values below pH 6.5
SDS
complete inhibition at 0.1%
Spatholobus suberectus extract
the extract has a strong inhibitory effect on LDH-5 expression and activity inboth estrogen-dependent and estrogen-independent human breast cancer cells
-
Tartronate
-
dead-end inhibitor, competitive inhibitor versus L-lactate
Thionicotinamide adenine dinucleotide
-
competitive versus NAD+ and noncompetitive versus L-lactate
Tris/maleate buffer
-
at pH 5.4
Urea
-
enzyme activity and electrophoretic pattern of LDH-A4 and malate dehydrogenase, EC 1.1.1.37, compared in relation to heat and urea inactivation, LDH is more sensitive than MDH, overview
Zn[Ac]2[2,2'-bipyridine]
-
analysis of interaction with the LDH isozymes and their modulation, significantly inhibits LDH in liver, kidney, and heart, but not in spleen, brain and skeletal muscle tissues, overview
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
[(2-methoxyethyl)amino](oxo)acetic acid
[(3,3-diphenylpropyl)amino](oxo)acetic acid
[(3-methoxypropyl)amino](oxo)acetic acid
[(3-methylbutyl)amino](oxo)acetic acid
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
[(4-chlorobenzyl)amino](oxo)acetic acid
[(4-methylbenzyl)amino](oxo)acetic acid
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
[benzyl(methyl)amino](oxo)acetic acid
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
-
-
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
-
-
(abieta-8,11,13-trien-18-ylamino)(oxo)acetic acid
-
-
(benzylamino)(oxo)acetic acid
-
-
(benzylamino)(oxo)acetic acid
-
-
(benzylamino)(oxo)acetic acid
-
-
(heptylamino)(oxo)acetic acid
-
-
(heptylamino)(oxo)acetic acid
-
-
(heptylamino)(oxo)acetic acid
-
-
(hexylamino)(oxo)acetic acid
-
-
(hexylamino)(oxo)acetic acid
-
-
(hexylamino)(oxo)acetic acid
-
-
(nonylamino)(oxo)acetic acid
-
-
(nonylamino)(oxo)acetic acid
-
-
(nonylamino)(oxo)acetic acid
-
-
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
([2-cyano-4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]-2-methoxyphenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
([4-[2-([5-hydroxy-2-[(4-methoxybenzyl)carbamoyl]-4-oxo-4H-chromen-8-yl]oxy)ethyl]phenyl]amino)(oxo)acetic acid
-
-
1-[7-[3,4-dihydroxy-2-imino-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-8-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalen-1-yl]ethanone
-
-
1-[7-[3,4-dihydroxy-2-imino-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-8-yl]-2,3,8-trihydroxy-6-methyl-4-(propan-2-yl)naphthalen-1-yl]ethanone
-
-
2,3-dihydroxy-4,6,7-trimethylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-4,6,7-trimethylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6,7-dimethyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6,7-dimethyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6,7-dimethyl-4-propylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-(propan-2-yl)-7-[4-(trifluoromethyl)benzyl]naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-(propan-2-yl)-7-[4-(trifluoromethyl)benzyl]naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(2-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(2-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(3-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(3-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(4-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
2,3-dihydroxy-6-methyl-7-(4-methylbenzyl)-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
3,5-dihydroxynaphthalene-2-carboxylic acid
-
-
3,5-dihydroxynaphthalene-2-carboxylic acid
-
-
3,7-dihydroxynaphthalene-2-carboxylic acid
-
-
3,7-dihydroxynaphthalene-2-carboxylic acid
-
-
4,7-dibromo-3-hydroxynaphthalene-2-carboxylic acid
-
-
4,7-dibromo-3-hydroxynaphthalene-2-carboxylic acid
-
-
4-(ethylcarbamoyl)benzoic acid
-
-
4-(ethylcarbamoyl)benzoic acid
-
-
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
-
trophozoites are the most susceptible stages to exposure to 4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
4-hydroxy-1,2,5-oxadiazole-3-carboxylic acid
-
-
6,6'-disulfanediyldipyridine-3-carboxylic acid
-
-
6,6'-disulfanediyldipyridine-3-carboxylic acid
-
-
7-(4-chlorobenzyl)-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
7-(4-chlorobenzyl)-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-4,6-dimethylnaphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-6-methyl-4-(propan-2-yl)naphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
-
-
7-benzyl-2,3-dihydroxy-6-methyl-4-propylnaphthalene-1-carboxylic acid
-
-
8'-acetyl-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8-carboxylic acid
-
-
8'-acetyl-1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalene-8-carboxylic acid
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl acetate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl acetate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl butanoate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl butanoate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl pentanoate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl pentanoate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl propanoate
-
-
8'-acetyl-8-cyano-1',6,6',7,7'-pentahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)-2,2'-binaphthalen-1-yl propanoate
-
-
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-(2-[4-[(carboxycarbonyl)amino]-3-methoxyphenyl]ethoxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-(phenylamino)naphthalene-1-sulfonic acid
-
-
8-(phenylamino)naphthalene-1-sulfonic acid
-
-
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-([4-[(carboxycarbonyl)amino]-3-methoxybenzyl]oxy)-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid
-
-
8-[8-acetyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-3,4-dihydroxy-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-2-one
-
-
8-[8-acetyl-1,6,7-trihydroxy-3-methyl-5-(propan-2-yl)naphthalen-2-yl]-3,4-dihydroxy-7-methyl-5-(propan-2-yl)-2H-naphtho[1,8-bc]furan-2-one
-
-
ADP
-
isoenzyme I and II, inhibition is reduced by MgCl2
ADP
-
ADP is a more severe inhibitor and has a more severe inhibitory effect on the lactate oxidation reaction. But its relative inhibition on reverse reactions is weak at low ADP concentrations
ADP
-
competitive with NADH
Ag+
-
-
Ag+
complete inhibition at 1 mM
amino(oxo)acetic acid
-
-
amino(oxo)acetic acid
-
-
amino(oxo)acetic acid
-
-
AMP
-
isoenzyme I and II, inhibition is reduced by MgCl2
ATP
-
10 mM, 40% loss of activity
ATP
-
isoenzyme I and II, inhibition is reduced by MgCl2
ATP
-
inhibitory effects of ATP on both directions are weak and similar as both rates remain above 80% in the presence of 8 mM ATP
ATP
-
competitive with respect to NADH at pH 7.0 and at pH 6.2
ATP
-
at neutral or alkaline pH ATP behaves as a weak competitive inhibitor, potent inhibitor at acid pH values
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')copper
-
-
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')copper
-
-
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')zinc
-
-
bis(acetatato-kO)(biphenyl-2,2'-diyl-k2C2,C2')zinc
-
-
Cd2+
-
partial
Cd2+
-
at high concentration
Cd2+
-
0.1 mM and 1.0 mM, weak inhibition
Chloroquine
-
IC50: 5.5 mM
Co2+
-
both directions
Co2+
-
0.1 mM and 1.0 mM, weak inhibition
Cu2+
-
both directions
Cu2+
-
0.1 mM and 1.0 mM, weak inhibition
Cu2+
6 h, 60% decrease in activity
Cu2+
complete inhibition at 1 mM
D-fructose 1,6-bisphosphate
-
slightly inhibits activity of hybrid enzyme constructed from fragments of the LDH genes from Bacillus stearothermophilus (coding for aa 15-100) and Bacillus megaterium (coding for aa 101-331)
D-fructose 1,6-bisphosphate
-
slightly inhibits activity of hybrid enzyme constructed from fragments of the LDH genes from Bacillus stearothermophilus (coding for aa 15-100) and Bacillus megaterium (coding for aa 101-331)
Fe2+
-
1 mM, 94% of initial activity
Fe2+
6 h, 70% decrease in activity
Fe2+
74% inhibition at 1 mM
fructose 1,6-bisphosphate
-
10 mM significantly inhibits LDHB by 23% in a non-competitive manner. Level of inhibition seems to be even more pronounced at pH 6.2, compared to the optimal pH 6.8. At the more acidic pH and in the presence of 10 mM, LDHB shows a 42% decrease in activity
fructose 1,6-bisphosphate
-
10 mM significantly inhibits LDHA abd LDHB (by 86%) in a non-competitive manner. Level of inhibition seems to be even more pronounced at pH 6.2, compared to the optimal pH 6.8. At the more acidic pH and in the presence of 10 mM, there is almost a 97% decrease in activity for LDHB
fructose 1,6-diphosphate
-
-
fructose 1,6-diphosphate
-
activation at low concentrations, inhibition at high concentrations
gossylic nitrile 1,1'-diacetate
-
gossylic nitrile 1,1'-diacetate
-
-
gossylic nitrile 1,1'-diacetate
-
-
gossylic nitrile 1,1'-diacetate
-
gossypol
competitive with NADH
gossypol
-
a polyphenolic binaphthyl disesquiterpene from Gossypium sp.
gossypol lactone
-
GTP
-
-
Hg2+
-
HgCl2
Hg2+
Molinema dessetae
-
-
iodoacetamide
-
slight
iodoacetate
-
-
iodoacetate
Molinema dessetae
-
-
L-lactate
-
substrate inhibition is uncompetitive
L-lactate
-
product inhibition
methylmalonate
-
-
methylmalonate
-
IC50: 4.6 mM (enzyme from brain), 4.6 mM (enzyme from liver)
Mg2+
-
both directions
Mg2+
-
1 mM, 96% of initial activity
Mn2+
-
both directions
Mn2+
-
1 mM, 82% of initial activity
NAD+
-
40 mM, complete loss of activity
NAD+
-
substrate inhibition due to an abortive NAD+-pyruvate complex reducing the steady state concentration of functional LDH
NAD+
-
competitive with respect to NADH, reduction of pyruvate
NAD+
-
product inhibition
NAD+
-
product inhibition
NAD+
7% inhibition at 0.5 mM
naphthalene-2,6-dicarboxylic acid
-
-
naphthalene-2,6-dicarboxylic acid
-
-
naphthalene-2,6-disulfonic acid
-
-
naphthalene-2,6-disulfonic acid
-
-
Ni2+
-
partial
oxalate
-
0.5 mM, 28% inhibition
oxalate
-
both directions
oxalate
Molinema dessetae
-
noncompetitive with pyruvate, competitive with lactate
oxaloacetate
-
-
oxamate
-
0.5 mM, 41% inhibition
oxamate
-
dead-end inhibitor, competitive inhibitor versus pyruvate
oxamate
-
specific inhibitor of L-LDH
oxamate
an inhibitor of gluconeogenesis, which suppresses cell proliferation through induction of G2/M or G0/G1 cell cycle arrest and promotion of apoptosis
oxamate
Molinema dessetae
-
competitive with pyruvate, noncompetitive with lactate
oxamate
-
0.1 mM, inhibition of NADH oxidation rate by about 60%
oxo(pentadecylamino)acetic acid
-
-
oxo(pentadecylamino)acetic acid
-
-
oxo(pentadecylamino)acetic acid
-
-
oxo(phenylamino)acetic acid
-
-
oxo(phenylamino)acetic acid
-
-
oxo(phenylamino)acetic acid
-
-
oxo[(2-phenylethyl)amino]acetic acid
-
-
oxo[(2-phenylethyl)amino]acetic acid
-
-
oxo[(2-phenylethyl)amino]acetic acid
-
-
oxo[(2-phenylpropyl)amino]acetic acid
-
-
oxo[(2-phenylpropyl)amino]acetic acid
-
-
oxo[(2-phenylpropyl)amino]acetic acid
-
-
oxo[(3-phenylpropyl)amino]acetic acid
-
-
oxo[(3-phenylpropyl)amino]acetic acid
-
-
oxo[(3-phenylpropyl)amino]acetic acid
-
-
oxo[(4-phenylbutan-2-yl)amino]acetic acid
-
-
oxo[(4-phenylbutan-2-yl)amino]acetic acid
-
-
oxo[(4-phenylbutan-2-yl)amino]acetic acid
-
-
oxo[(4-phenylbutyl)amino]acetic acid
-
-
oxo[(4-phenylbutyl)amino]acetic acid
-
-
oxo[(4-phenylbutyl)amino]acetic acid
-
-
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
-
-
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
-
-
oxo[(tetrahydrofuran-2-ylmethyl)amino]acetic acid
-
-
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
-
-
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
-
-
oxo[[1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl]amino]acetic acid
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
Molinema dessetae
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
slight
p-hydroxymercuribenzoate
-
-
p-hydroxymercuribenzoate
-
-
phosphate
-
-
phosphate
phosphate acts as a strong activator of LDHB
phosphate
-
slight activation of non-activated enzyme, inhibition of fructose 1,6-diphosphate activated enzyme
phosphoenolpyruvate
-
-
pyruvate
-
substrate inhibition is uncompetitive
pyruvate
-
low substrate inhibition
pyruvate
-
substrate inhibition
pyruvate
-
substrate inhibition due to an abortive NAD+-pyruvate complex reducing the steady state concentration of functional LDH
pyruvate
-
substrate inhibition
pyruvate
-
substrate inhibition by pyruvate is related to the formation of an enzyme-pyruvate-NAD+complex
pyruvate
-
substrate inhibition
pyruvate
-
substrate inhibition in wild type enzyme, lower substrate inhibition in mutant S163L
pyruvate
-
substrate inhibition
pyruvate
-
the enzyme shows substrate inhibition, inhibition mechanism, overview
pyruvate
-
at high concentrations
pyruvate
-
strong substrate inhibition at high concentrations, fructose 1,6-diphosphate activated enzyme
Zn2+
-
-
Zn2+
complete inhibition at 1 mM
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(2-ethylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(2-methoxyethyl)amino](oxo)acetic acid
-
-
[(2-methoxyethyl)amino](oxo)acetic acid
-
-
[(2-methoxyethyl)amino](oxo)acetic acid
-
-
[(3,3-diphenylpropyl)amino](oxo)acetic acid
-
-
[(3,3-diphenylpropyl)amino](oxo)acetic acid
-
-
[(3,3-diphenylpropyl)amino](oxo)acetic acid
-
-
[(3-methoxypropyl)amino](oxo)acetic acid
-
-
[(3-methoxypropyl)amino](oxo)acetic acid
-
-
[(3-methoxypropyl)amino](oxo)acetic acid
-
-
[(3-methylbutyl)amino](oxo)acetic acid
-
-
[(3-methylbutyl)amino](oxo)acetic acid
-
-
[(3-methylbutyl)amino](oxo)acetic acid
-
-
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(3-methylphenyl)(phenyl)amino](oxo)acetic acid
-
-
[(4-chlorobenzyl)amino](oxo)acetic acid
-
-
[(4-chlorobenzyl)amino](oxo)acetic acid
-
-
[(4-chlorobenzyl)amino](oxo)acetic acid
-
-
[(4-methylbenzyl)amino](oxo)acetic acid
-
-
[(4-methylbenzyl)amino](oxo)acetic acid
-
-
[(4-methylbenzyl)amino](oxo)acetic acid
-
-
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
-
-
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
-
-
[(furan-2-ylmethyl)(methyl)amino](oxo)acetic acid
-
-
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
-
-
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
-
-
[(naphthalen-1-ylmethyl)amino](oxo)acetic acid
-
-
[benzyl(methyl)amino](oxo)acetic acid
-
-
[benzyl(methyl)amino](oxo)acetic acid
-
-
[benzyl(methyl)amino](oxo)acetic acid
-
-
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(2-methylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-benzylpiperidin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[bis(4-phenylpiperazin-1-yl)amino](oxo)acetic acid
-
-
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
-
-
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
-
-
[[2-(4-bromophenyl)ethyl]amino](oxo)acetic acid
-
-
additional information
-
the Aggregatibacter actinomycetemcomitans L-lactate dehydrogenase, unlike homologous enzymes, is not feedback inhibited by pyruvate, pyruvate is a poor inhibitor of L-lactate dehydrogenase activity
-
additional information
-
loss of LDH activity with increasing pressure and time treatment due to the combined effects of denaturation and aggregation, overview
-
additional information
CpLDH does not display any measurable inhibition to pyruvate concentrations up to at least 20 mM in contrast to many other LDHs
-
additional information
-
CpLDH does not display any measurable inhibition to pyruvate concentrations up to at least 20 mM in contrast to many other LDHs
-
additional information
-
blockade of nicotinic cholinoreceptors significantly decreases total LDH activity and H- and M-isoform activities in neurons. LDH activity decreases by 41.5% and 71% in conditions of partial and complete blockade, respectively. Decreases in H-isoform activity are by 25% in partial blockade and 42% in complete blockade and decreases in M-isoform activity are by 35% and 62%. In partial and complete blockade, the activity of LDH and its H- and M-isoforms decrease significantly in proportion to the number of blocked nicotinic cholinoreceptors. In satellite gliocytes, increases in the extent of blockade are associated with decreases in the activity only of the M-isoform (by 43% in partial blockade and 55.5% in complete blockade), while the activity of the H-isoform does not change. In partial blockade, the LDH isoenzyme profile of satellite gliocytes shifts towards the neuronal isoform, while in complete blockade there is no difference from the LDH isoenzyme profile of intact neurons
-
additional information
-
lack of substrate inhibition
-
additional information
-
inhibition mechanism, the plasmodial enzyme possesses a five-residue insertion in the substrate-specificity loop and exhibits less marked substrate inhibition than its mammalian counterparts, overview
-
additional information
-
short-term storage in Krebs-Henseleit buffer for 24 h at 4°C does not affect LDH activity, but a 42% decline occurs at 23°C. After 48 h, activity declines 11% at 4°C and 98% at 23°C. Frozen storage results in a 40% loss at -80°C and a 79% loss at -20°C
-
additional information
-
no inhibition by nitric oxide
-
additional information
-
NADH, NAD+, ATP, ADP, AMP, and pyruvate inhibit the interaction of the heart-type isozyme with acidic phospholipid liposomes, potency in descending order. NADP+, GTP, CTP, UTP and lactate are ineffective, overview
-